Abstract
Members of the serine–arginine protein kinase (SRPK) family, SRPK1 and SRPK2, phosphorylate the hepatitis B core protein (Cp) and are crucial for pregenomic RNA encapsidation during viral nucleocapsid assembly. Among them, SRPK2 exhibits higher kinase activity toward Cp. In this study, we identified Cp sites that are phosphorylated by SRPK2 and demonstrated that the kinase utilizes an SRPK-specific docking groove to interact with and regulate the phosphorylation of the C-terminal arginine rich domain of Cp. We determined that direct interaction between the docking groove of SRPK2 and unphosphorylated Cp inhibited premature viral capsid assembly in vitro, whereas the phosphorylation of the viral protein reactivated the process. Pull-down assays together with the new cryo-electron microscopy structure of the HBV capsid in complex with SRPK2 revealed that the kinases decorate the surface of the viral capsid by interacting with the C-terminal domain of Cp, underscoring the importance of the docking interaction in regulating capsid assembly and pregenome packaging. Moreover, SRPK2-knockout in HepG2 cells suppressed Cp phosphorylation, indicating that SRPK2 is an important cellular kinase for HBV life cycle.
Funder
Hong Kong Research Grants Council
Faculty of Science, Chinese University of Hong Kong
Research Committee Group Research Scheme, Chinese University of Hong Kong
State Key Laboratory for Agrobiotechnology ITC fund
Publisher
Public Library of Science (PLoS)
Reference56 articles.
1. Global, regional, and national burden of hepatitis B, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019.;GBDHB Collaborators;Lancet Gastroenterol Hepatol,2022
2. Hepatitis B: Epidemiology and prevention in developing countries;E Franco;World J Hepatol,2012
3. Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis;S Koklu;Clin Gastroenterol Hepatol,2013
4. Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease;JY Cho;Gut,2014
5. Effectiveness of hepatitis B treatment in clinical practice;SJ Scaglione;Gastroenterology,2012